Carcino Embryonic Antigen (CEA), in Visit Clinic

A high CEA (carcinoembryonic antigen) level can suggest cancer—most often colorectal or other adenocarcinomas—but isn’t diagnostic by itself. Noncancer causes include smoking, inflammation, liver disease, and benign gastrointestinal conditions. CEA often reflects tumor burden and is used to monitor treatment or detect recurrence. A single elevated value warrants repeat testing and further clinical evaluation, possibly including imaging or biopsy.

CEA (carcinoembryonic antigen) is normally under about 3 ng/mL in non‑smokers and under 5 ng/mL in smokers. Levels above these thresholds can raise suspicion for malignancy but are not diagnostic—benign conditions and smoking can also elevate CEA. Very high values (for example >20 ng/mL) often indicate advanced or metastatic disease. Serial trends and clinical context determine interpretation.

Yes. CEA can be raised by many non-cancer conditions—smoking, chronic lung disease, inflammatory bowel disease, pancreatitis, liver disease (including benign lesions and cirrhosis), infections, recent surgery, and some benign tumors. Mild elevations are common and CEA alone does not diagnose cancer; clinicians use trends and other tests (imaging, biopsies) to determine cause and need for further investigation.

CEA can be elevated in liver cancer, particularly when the liver is affected by metastatic colorectal cancer. Primary liver cancer (hepatocellular carcinoma) more commonly raises AFP rather than CEA, so CEA is neither sensitive nor specific for primary liver cancer. CEA may also rise with benign liver disease and smoking, so it’s used mainly for monitoring treatment or recurrence, not for sole diagnosis.

Carcinoembryonic antigen (CEA) can be a useful tumor marker for monitoring treatment response and detecting recurrence—especially in colorectal cancer—when levels were elevated before therapy. It is not reliable for screening or diagnosing cancer because sensitivity and specificity are limited and levels can rise with smoking, inflammation, liver disease, and other cancers. Interpret CEA trends alongside imaging and clinical findings.

High risk for carotid endarterectomy (CEA) includes severe cardiac or pulmonary disease—recent myocardial infarction, unstable angina, advanced heart failure, or oxygen‑dependent COPD—significant renal dysfunction, prior neck radiation or surgery, recurrent stenosis after earlier CEA, high cervical lesions above C2, contralateral vocal‑cord paralysis (risk of bilateral nerve injury), advanced frailty, or other comorbidities increasing perioperative stroke, MI, or death.